Daniel Medenwald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel Medenwald has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jörg Andreas Müller
Department of Radiation Oncology, University Hospital Halle (Saale), Halle (Saale), Germany
3 shared publications - Dirk Vordermark
Department of Radiation Oncology, University Hospital Halle (Saale), Halle (Saale), Germany
2 shared publications Jörg Andreas Müller
Department of Radiation Oncology, University Hospital Halle, Halle (Saale), Germany
2 shared publications- Ahmed Bedir
Department of Radiation Oncology, Otto von Guericke University Magdeburg Medical Faculty, Magdeburg, Germany
1 shared publication Alexander Kluttig
Klinische Krebsregister Sachsen-Anhalt GmbH, Magdeburg, Deutschland
1 shared publicationAndreas Stang
Cancer Registry of North Rhine-Westphalia, Bochum, Germany
1 shared publication
Latest Publications
- Open Access
Itraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study
Preclinical studies and data from other cancers suggest that inhibition of the Hedgehog (Hh) pathway also has antiproliferative effects on glioma cells. A key component of this pathway is the Smoothened (SMO) protein, which is expressed in high-grade gliomas. Itraconazole (ITRA), a widely used antifungal agent, inhibits SMO, the PI3K/AKT/mTOR pathway, and the VEGF/VEGFR-2 axis—both of which are critical for GBM progression and angiogenesis. This protocol describes a prospective, single-center, dose-escalation phase I study with the classical 3 + 3 design in order to determine the MTD of ITRA. The study enrolls patients with a newly histologically confirmed diagnosis of GBM, without previous treatment except surgery. They will be treated with standard RT schedule (60 Gy in 30 fractions) with concurrent TMZ 75 mg/m2 and ITRA 2 × 100 mg, 200 mg, or 300 mg daily. The primary endpoint is to determine the MTD of ITRA given concurrently with RT + TMZ. Secondary endpoints include safety and tolerability of ITRA, overall survival (OS), progression-free survival (PFS), overall objective response rate, use of corticosteroids, treatment compliance, and health-related quality of life (EORTC QLQ-C30 and BN20). Participants will be monitored for one week post-treatment. All relevant statistics will be primarily descriptive.
Open AccessItraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study
Preclinical studies and data from other cancers suggest that inhibition of the Hedgehog (Hh) pathway also has antiproliferative effects on glioma cells. A key component of this pathway is the Smoothened (SMO) protein, which is expressed in high-grade gliomas. Itraconazole (ITRA), a widely used antifungal agent, inhibits SMO, the PI3K/AKT/mTOR pathway, and the VEGF/VEGFR-2 axis—both of which are critical for GBM progression and angiogenesis. This protocol describes a prospective, single-center, dose-escalation phase I study with the classical 3 + 3 design in order to determine the MTD of ITRA. The study enrolls patients with a newly histologically confirmed diagnosis of GBM, without previous treatment except surgery. They will be treated with standard RT schedule (60 Gy in 30 fractions) with concurrent TMZ 75 mg/m2 and ITRA 2 × 100 mg, 200 mg, or 300 mg daily. The primary endpoint is to determine the MTD of ITRA given concurrently with RT + TMZ. Secondary endpoints include safety and tolerability of ITRA, overall survival (OS), progression-free survival (PFS), overall objective response rate, use of corticosteroids, treatment compliance, and health-related quality of life (EORTC QLQ-C30 and BN20). Participants will be monitored for one week post-treatment. All relevant statistics will be primarily descriptive.
- Open Access
Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
Introduction: Video-assisted thoracoscopic surgery (VATS) lobectomy is a commonly employed surgical technique for the management of operable early stage non-small cell lung cancer (NSCLC). This procedure, however, is dependent on the patient’s ability to tolerate surgery. In light of this, stereotactic ablative radiotherapy (SABR) has emerged as a viable alternative treatment strategy for patients who are inoperable or who refuse surgery. Considering the lack of randomised controlled trials and the increased risk of bias in observational cohort studies, this study protocol proposes an emulated target trial design to investigate the causal effect of SABR, in comparison to VATS, on overall survival in operable early stage NSCLC patients. Methods and analysis: Data on NSCLC patients will be collected from routinely collected university hospital records linked with German cancer registry data. This study protocol was developed using the target trial methodology outlined by Hernan et al . The protocol establishes specific parameters for key trial components in order to mitigate bias in the analysis of observational data and to facilitate the calculation of causal estimands. The target trial design that would be emulated is a multicentre open-label two-parallel arm superiority randomised trial. Mediators and confounding variables were determined through the use of a directed acyclic graph. The statistical analysis aims to measure the per-protocol and intention to treat effect of SABR versus VATS within 3 months of diagnosis, on survival, through the difference in restricted mean survival times, using weighted non-parametric Kaplan-Meier curves. Ethics and dissemination: The Ethics Committee of the Medical Faculty of Martin Luther University Halle-Wittenberg with an approved addendum with Dnr 2023–112 has approved this study. The study uses anonymised routinely collected hospital and cancer registry data in accordance with applicable data protection regulations. Results will be disseminated through peer-reviewed publications and presentations at scientific conferences.
Open AccessStereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
Introduction: Video-assisted thoracoscopic surgery (VATS) lobectomy is a commonly employed surgical technique for the management of operable early stage non-small cell lung cancer (NSCLC). This procedure, however, is dependent on the patient’s ability to tolerate surgery. In light of this, stereotactic ablative radiotherapy (SABR) has emerged as a viable alternative treatment strategy for patients who are inoperable or who refuse surgery. Considering the lack of randomised controlled trials and the increased risk of bias in observational cohort studies, this study protocol proposes an emulated target trial design to investigate the causal effect of SABR, in comparison to VATS, on overall survival in operable early stage NSCLC patients. Methods and analysis: Data on NSCLC patients will be collected from routinely collected university hospital records linked with German cancer registry data. This study protocol was developed using the target trial methodology outlined by Hernan et al . The protocol establishes specific parameters for key trial components in order to mitigate bias in the analysis of observational data and to facilitate the calculation of causal estimands. The target trial design that would be emulated is a multicentre open-label two-parallel arm superiority randomised trial. Mediators and confounding variables were determined through the use of a directed acyclic graph. The statistical analysis aims to measure the per-protocol and intention to treat effect of SABR versus VATS within 3 months of diagnosis, on survival, through the difference in restricted mean survival times, using weighted non-parametric Kaplan-Meier curves. Ethics and dissemination: The Ethics Committee of the Medical Faculty of Martin Luther University Halle-Wittenberg with an approved addendum with Dnr 2023–112 has approved this study. The study uses anonymised routinely collected hospital and cancer registry data in accordance with applicable data protection regulations. Results will be disseminated through peer-reviewed publications and presentations at scientific conferences.
- Open Access
Patterns of Radiation Therapy During the COVID-19 Pandemic: Results from the Multicenter, Cross-Sectoral Registry of the German National Pandemic Cohort Network (NAPKON)
Background: Cancer patients receiving or having received radiotherapy (RT) represent a clinically vulnerable group during the COVID-19 pandemic. However, systematic data on their clinical course, comorbidities, and vaccination status are limited. The German National Pandemic Cohort Network (NAPKON), established to systematically collect comprehensive clinical data on COVID-19 patients nationwide, provides a unique opportunity to address this gap. This study aimed to describe radiation therapy patterns and COVID-19-related clinical characteristics among patients documented within the NAPKON Cross-Sectoral Platform (SUEP). Methods: This multicenter, descriptive analysis was conducted within the framework of the German National Pandemic Cohort Network (NAPKON). All patients with documented RT and confirmed SARS-CoV-2 infection were identified in the SUEP database. RT was classified relative to the documented infection date as occurring before, during, or after infection. Demographic, clinical, laboratory, imaging, and vaccination data were extracted and analyzed descriptively. Due to the small sample size, no correlation or multivariable analyses were performed. Results: A total of n = 90 patients were included in the analysis. The median age was 65 years (range 22–90), and 56% were male. Most patients (93%) received one course of RT, most frequently targeting specific organ systems (54%), while total body irradiation was performed in 4%. The median radiation dose was 45 Gy (IQR 30–60). Among 68 patients with evaluable timing information, RT had been administered before infection in 53 patients (77.9%), during infection in 3 patients (4.4%), and after infection in 12 patients (17.6%). At the time of SARS-CoV-2 detection, 76% of patients experienced a phase without complications, 19% a phase with complications, and 2% a critical phase. The majority of vaccinated individuals had received Comirnaty (BioNTech/Pfizer; 80%). COVID-19-typical findings were identified in 18% of chest X-rays and 27% of CT scans. Clinical and laboratory characteristics showed no substantial differences by hospital length of stay. Conclusions: Patients with documented RT and SARS-CoV-2 infection in the NAPKON registry predominantly experienced mild or moderate COVID-19 courses and showed a relatively high vaccination uptake. However, due to the descriptive study design and the absence of a control group, these findings should not be interpreted as being attributable to RT itself but rather as a characterization of this registry cohort. Importantly, the cohort mainly comprised patients with a history of RT before SARS-CoV-2 infection, whereas only a small minority received RT during infection. Although the analysis was descriptive and limited by missing data, it demonstrates the feasibility and scientific value of integrating oncologic subcohorts within national pandemic research networks. Continued longitudinal analyses will be essential to further characterize outcomes of patients with cancer and RT in future pandemics.
Open AccessPatterns of Radiation Therapy During the COVID-19 Pandemic: Results from the Multicenter, Cross-Sectoral Registry of the German National Pandemic Cohort Network (NAPKON)
Background: Cancer patients receiving or having received radiotherapy (RT) represent a clinically vulnerable group during the COVID-19 pandemic. However, systematic data on their clinical course, comorbidities, and vaccination status are limited. The German National Pandemic Cohort Network (NAPKON), established to systematically collect comprehensive clinical data on COVID-19 patients nationwide, provides a unique opportunity to address this gap. This study aimed to describe radiation therapy patterns and COVID-19-related clinical characteristics among patients documented within the NAPKON Cross-Sectoral Platform (SUEP). Methods: This multicenter, descriptive analysis was conducted within the framework of the German National Pandemic Cohort Network (NAPKON). All patients with documented RT and confirmed SARS-CoV-2 infection were identified in the SUEP database. RT was classified relative to the documented infection date as occurring before, during, or after infection. Demographic, clinical, laboratory, imaging, and vaccination data were extracted and analyzed descriptively. Due to the small sample size, no correlation or multivariable analyses were performed. Results: A total of n = 90 patients were included in the analysis. The median age was 65 years (range 22–90), and 56% were male. Most patients (93%) received one course of RT, most frequently targeting specific organ systems (54%), while total body irradiation was performed in 4%. The median radiation dose was 45 Gy (IQR 30–60). Among 68 patients with evaluable timing information, RT had been administered before infection in 53 patients (77.9%), during infection in 3 patients (4.4%), and after infection in 12 patients (17.6%). At the time of SARS-CoV-2 detection, 76% of patients experienced a phase without complications, 19% a phase with complications, and 2% a critical phase. The majority of vaccinated individuals had received Comirnaty (BioNTech/Pfizer; 80%). COVID-19-typical findings were identified in 18% of chest X-rays and 27% of CT scans. Clinical and laboratory characteristics showed no substantial differences by hospital length of stay. Conclusions: Patients with documented RT and SARS-CoV-2 infection in the NAPKON registry predominantly experienced mild or moderate COVID-19 courses and showed a relatively high vaccination uptake. However, due to the descriptive study design and the absence of a control group, these findings should not be interpreted as being attributable to RT itself but rather as a characterization of this registry cohort. Importantly, the cohort mainly comprised patients with a history of RT before SARS-CoV-2 infection, whereas only a small minority received RT during infection. Although the analysis was descriptive and limited by missing data, it demonstrates the feasibility and scientific value of integrating oncologic subcohorts within national pandemic research networks. Continued longitudinal analyses will be essential to further characterize outcomes of patients with cancer and RT in future pandemics.
- Open Access
- 24 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
Evaluation of the updated 2022 lung-GPA in NSCLC adenocarcinoma patients with brain metastases: analysis of prognostic factors in a German clinical cohort
Background: Lung cancer is the most frequent source of brain metastases (BMs), with 20-40% of patients with non-small cell lung cancer (NSCLC) developing BMs during the course of disease. The NSCLC-GPA (Graded Prognostic Assessment), developed by Sperduto et al., aims to estimate overall survival (OS) in lung cancer patients with BMs based on multiple prognostic factors. This study aimed to validate the applicability and prognostic relevance of the updated 2022 NSCLC-GPA in a German clinical cohort, with particular attention to programmed death-ligand 1 (PD-L1) expression and treatment-related outcomes. Methods: We retrospectively analyzed patients with NSCLC and BMs treated between 2020 and 2022 at a German university hospital. GPA scores were calculated using established parameters: age, Karnofsky Performance Status (KPS), number of BMs, presence of extracranial metastases (ECM), EGFR and ALK mutation status, and PD-L1 expression. Due to the low number of non-adenocarcinoma (NAC) cases in our cohort, only patients with adenocarcinoma (AC) were included. Univariate and multivariate Cox regression models, log-rank tests, and Kaplan–Meier curves for illustrative purposes were used to evaluate associations between prognostic factors and OS. Results: A total of 110 AC patients met the inclusion criteria. Median OS was 10 months (range: 6-11). Patients with GPA scores of 0-1 and 1.5-2 had significantly worse outcomes compared with the reference group (GPA 3.5-4; median OS: 36 months), with median OS times of 3 and 8 months, respectively (HR: 8.34, 95% CI: 2.53-27.5, p = 0.0005 and HR: 5.24, 95% CI: 1.584-17.33, p = 0.0067). Patients with a GPA of 2.5-3 had a median OS of 22.5 months (HR: 1.6, 95% CI: 0.469-5.45, p = 0.453), which was not statistically significant. Older age (≥ 70 years; HR: 1.95, 95% CI: 1.23-3.11, p = 0.0047), low KPS (KPS ≤ 70; HR: 3.88, 95% CI: 2.33-6.46, p < 0.0001), a higher number of BMs (HR: 1.58, 95% CI: 1.03-2.41, p = 0.035), and the presence of ECM (HR: 2.62, 95% CI: 1.66-4.13, p < 0.0001) were all significantly associated with decreased OS. In the multivariate analysis, low KPS and ECM remained independently significant prognostic factors. PD-L1 expression showed no significant association with OS. Conclusion: Despite shorter OS outcomes in our cohort, the 2022 NSCLC-GPA proved to be a valuable prognostic tool, with lower scores consistently associated with poorer outcomes. In addition, older age, low KPS, ECM, and a higher number of BMs were identified as prognostic factors, with low KPS and ECM remaining independent prognostic factors in the multivariate analysis.
- 24 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
Open AccessEvaluation of the updated 2022 lung-GPA in NSCLC adenocarcinoma patients with brain metastases: analysis of prognostic factors in a German clinical cohort
Background: Lung cancer is the most frequent source of brain metastases (BMs), with 20-40% of patients with non-small cell lung cancer (NSCLC) developing BMs during the course of disease. The NSCLC-GPA (Graded Prognostic Assessment), developed by Sperduto et al., aims to estimate overall survival (OS) in lung cancer patients with BMs based on multiple prognostic factors. This study aimed to validate the applicability and prognostic relevance of the updated 2022 NSCLC-GPA in a German clinical cohort, with particular attention to programmed death-ligand 1 (PD-L1) expression and treatment-related outcomes. Methods: We retrospectively analyzed patients with NSCLC and BMs treated between 2020 and 2022 at a German university hospital. GPA scores were calculated using established parameters: age, Karnofsky Performance Status (KPS), number of BMs, presence of extracranial metastases (ECM), EGFR and ALK mutation status, and PD-L1 expression. Due to the low number of non-adenocarcinoma (NAC) cases in our cohort, only patients with adenocarcinoma (AC) were included. Univariate and multivariate Cox regression models, log-rank tests, and Kaplan–Meier curves for illustrative purposes were used to evaluate associations between prognostic factors and OS. Results: A total of 110 AC patients met the inclusion criteria. Median OS was 10 months (range: 6-11). Patients with GPA scores of 0-1 and 1.5-2 had significantly worse outcomes compared with the reference group (GPA 3.5-4; median OS: 36 months), with median OS times of 3 and 8 months, respectively (HR: 8.34, 95% CI: 2.53-27.5, p = 0.0005 and HR: 5.24, 95% CI: 1.584-17.33, p = 0.0067). Patients with a GPA of 2.5-3 had a median OS of 22.5 months (HR: 1.6, 95% CI: 0.469-5.45, p = 0.453), which was not statistically significant. Older age (≥ 70 years; HR: 1.95, 95% CI: 1.23-3.11, p = 0.0047), low KPS (KPS ≤ 70; HR: 3.88, 95% CI: 2.33-6.46, p < 0.0001), a higher number of BMs (HR: 1.58, 95% CI: 1.03-2.41, p = 0.035), and the presence of ECM (HR: 2.62, 95% CI: 1.66-4.13, p < 0.0001) were all significantly associated with decreased OS. In the multivariate analysis, low KPS and ECM remained independently significant prognostic factors. PD-L1 expression showed no significant association with OS. Conclusion: Despite shorter OS outcomes in our cohort, the 2022 NSCLC-GPA proved to be a valuable prognostic tool, with lower scores consistently associated with poorer outcomes. In addition, older age, low KPS, ECM, and a higher number of BMs were identified as prognostic factors, with low KPS and ECM remaining independent prognostic factors in the multivariate analysis.
- Open Access
- 10 December 2025
- Published by Springer Nature in Research Square
Real-World Evidence on the Management and Outcomes of Glioblastoma in Elderly Patients: A Monocentric Retrospective Analysis
Background: Glioblastoma (GBM) carries a poor prognosis, and elderly or frail patients are often underrepresented in randomized trials. This study evaluated real-world outcomes and prognostic factors in a monocentric cohort of elderly GBM patients. Methods: We retrospectively analyzed 67 patients aged ≥ 65 years with histologically confirmed GBM treated between 2014 and 2023 at a single institution. Overall survival (OS) was defined as the primary endpoint, and progression-free survival (PFS) as the secondary endpoint. Univariable and multivariable Cox proportional hazards regression models were applied to assess prognostic factors, including age, sex, Karnofsky Performance Status (KPS), extent of resection, and temozolomide (TMZ) administration. Sensitivity analyses included proportional hazards testing using Schoenfeld residuals. Results: The median OS was 7.0 months (interquartile range [IQR] 5.5–13.0), and the median PFS was 5.0 months (IQR 3.6–7.9). In multivariable analyses, increasing age was independently associated with worse OS (HR 1.07, 95% CI 1.00–1.14, p = 0.043) and PFS (HR 1.06, 95% CI 1.00–1.13, p = 0.038). Female sex was independently associated with improved OS (HR 0.50, 95% CI 0.26–0.98, p = 0.044) and PFS (HR 0.41, 95% CI 0.21–0.80, p = 0.009). Higher KPS was significantly associated with better OS (HR 0.98, 95% CI 0.96–1.00, p = 0.064) and PFS (HR 0.98, 95% CI 0.95–1.00, p = 0.024). Omission of TMZ predicted inferior OS (HR 2.41, 95% CI 1.24–4.66, p = 0.009) and PFS (HR 2.31, 95% CI 1.20–4.46, p = 0.013). Total resection was independently associated with improved OS (HR 0.50, 95% CI 0.26–0.96, p = 0.037), while showing a non-significant trend for PFS (HR 0.62, 95% CI 0.33–1.17, p = 0.14). Sensitivity analyses confirmed the robustness of the models, with no relevant violations of the proportional hazards assumption (global p = 0.164 for OS; p = 0.086 for PFS). Conclusions: In this real-world cohort of elderly GBM patients, survival outcomes remained poor despite multimodal therapy. Independent predictors of improved outcomes included younger age, female sex, higher performance status, total resection, and temozolomide therapy. Sensitivity analyses confirmed the robustness of the models, underscoring the prognostic relevance of established clinical and treatment-related factors and highlighting the need for individualized treatment approaches in this vulnerable population.
- 10 December 2025
- Published by Springer Nature in Research Square
Open AccessReal-World Evidence on the Management and Outcomes of Glioblastoma in Elderly Patients: A Monocentric Retrospective Analysis
Background: Glioblastoma (GBM) carries a poor prognosis, and elderly or frail patients are often underrepresented in randomized trials. This study evaluated real-world outcomes and prognostic factors in a monocentric cohort of elderly GBM patients. Methods: We retrospectively analyzed 67 patients aged ≥ 65 years with histologically confirmed GBM treated between 2014 and 2023 at a single institution. Overall survival (OS) was defined as the primary endpoint, and progression-free survival (PFS) as the secondary endpoint. Univariable and multivariable Cox proportional hazards regression models were applied to assess prognostic factors, including age, sex, Karnofsky Performance Status (KPS), extent of resection, and temozolomide (TMZ) administration. Sensitivity analyses included proportional hazards testing using Schoenfeld residuals. Results: The median OS was 7.0 months (interquartile range [IQR] 5.5–13.0), and the median PFS was 5.0 months (IQR 3.6–7.9). In multivariable analyses, increasing age was independently associated with worse OS (HR 1.07, 95% CI 1.00–1.14, p = 0.043) and PFS (HR 1.06, 95% CI 1.00–1.13, p = 0.038). Female sex was independently associated with improved OS (HR 0.50, 95% CI 0.26–0.98, p = 0.044) and PFS (HR 0.41, 95% CI 0.21–0.80, p = 0.009). Higher KPS was significantly associated with better OS (HR 0.98, 95% CI 0.96–1.00, p = 0.064) and PFS (HR 0.98, 95% CI 0.95–1.00, p = 0.024). Omission of TMZ predicted inferior OS (HR 2.41, 95% CI 1.24–4.66, p = 0.009) and PFS (HR 2.31, 95% CI 1.20–4.46, p = 0.013). Total resection was independently associated with improved OS (HR 0.50, 95% CI 0.26–0.96, p = 0.037), while showing a non-significant trend for PFS (HR 0.62, 95% CI 0.33–1.17, p = 0.14). Sensitivity analyses confirmed the robustness of the models, with no relevant violations of the proportional hazards assumption (global p = 0.164 for OS; p = 0.086 for PFS). Conclusions: In this real-world cohort of elderly GBM patients, survival outcomes remained poor despite multimodal therapy. Independent predictors of improved outcomes included younger age, female sex, higher performance status, total resection, and temozolomide therapy. Sensitivity analyses confirmed the robustness of the models, underscoring the prognostic relevance of established clinical and treatment-related factors and highlighting the need for individualized treatment approaches in this vulnerable population.
- 19 October 2023
- Published by Springer Nature in Forum
- Vol. 38 (6) , 444-448
Leitlinienassoziierte Versorgungsforschung in der Onkologie unter Nutzung von Registerdaten
- 19 October 2023
- Published by Springer Nature in Forum
- Vol. 38 (6) , 444-448
Leitlinienassoziierte Versorgungsforschung in der Onkologie unter Nutzung von Registerdaten